NASDAQ:CMND Clearmind Medicine (CMND) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free CMND Stock Alerts $1.16 -0.03 (-2.52%) (As of 12:09 PM ET) Add Compare Share Share Today's Range$1.14▼$1.1950-Day Range$1.08▼$1.7352-Week Range$0.92▼$23.70Volume42,655 shsAverage Volume1.21 million shsMarket Capitalization$1.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Clearmind Medicine alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Clearmind Medicine Stock (NASDAQ:CMND)Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Read More CMND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMND Stock News HeadlinesMay 3, 2024 | americanbankingnews.comClearmind Medicine (NASDAQ:CMND) Shares Down 0.8% May 1, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Applies to Cease Being a Reporting Issuer in CanadaMay 6, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 30, 2024 | globenewswire.comClearmind Applies to Cease Being a Reporting Issuer in CanadaApril 17, 2024 | msn.comClearmind signs agreement for psychedelic compounds for mental disorders treatmentApril 17, 2024 | finance.yahoo.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 17, 2024 | globenewswire.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 11, 2024 | uk.investing.comClearmind Medicine advances trial for alcohol use disorder treatmentMay 6, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.April 10, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 10, 2024 | globenewswire.comClearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 9, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine CEO Issues Letter to ShareholdersApril 9, 2024 | globenewswire.comClearmind Medicine CEO Issues Letter to ShareholdersMarch 29, 2024 | uk.investing.comClearmind Medicine files tenth patent for depression treatmentMarch 27, 2024 | finanznachrichten.deSciSparc Ltd: SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | globenewswire.comClearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 19, 2024 | globenewswire.comBreakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in ChinaMarch 13, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeMarch 13, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | msn.comClearmind Medicine receives nod for delisting of shares from Canadian Securities ExchangeMarch 13, 2024 | globenewswire.comClearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | globenewswire.comClearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeMarch 12, 2024 | msn.comPodcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive BehaviorsFebruary 27, 2024 | msn.comEXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine CompoundsFebruary 27, 2024 | globenewswire.comClearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsFebruary 23, 2024 | globenewswire.comClearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderSee More Headlines Receive CMND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/06/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMND CUSIPN/A CIK1892500 Webwww.clearmindmedicine.com Phone604-260-1566FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-265.38% Return on Assets-121.95% Debt Debt-to-Equity Ratio0.01 Current Ratio1.96 Quick Ratio1.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.22 per share Price / Book0.28Miscellaneous Outstanding Shares1,690,000Free FloatN/AMarket Cap$2.01 million OptionableNot Optionable Beta1.06 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Adi Zuloff-Shani Ph.D. (Age 55)Chief Executive Officer Mr. Alan Mark Rootenberg B.Com. (Age 72)B.Comm, C.A., CPA, Chief Financial Officer Prof. Mark Haden M.S.W. (Age 69)Vice President of Business Development Mr. Gilad BabchukHead of Strategy & CommunicationKey CompetitorsNotable LabsNASDAQ:NTBLBiodexa PharmaceuticalsNASDAQ:BDRXBio-PathNASDAQ:BPTHQualigen TherapeuticsNASDAQ:QLGNPainReformNASDAQ:PRFXView All CompetitorsInstitutional OwnershipAdvisorShares Investments LLCSold 30,564 shares on 2/14/2024Ownership: 5.485%View All Institutional Transactions CMND Stock Analysis - Frequently Asked Questions How have CMND shares performed in 2024? Clearmind Medicine's stock was trading at $2.81 on January 1st, 2024. Since then, CMND shares have decreased by 58.7% and is now trading at $1.16. View the best growth stocks for 2024 here. Are investors shorting Clearmind Medicine? Clearmind Medicine saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 160,200 shares, a decrease of 10.4% from the March 31st total of 178,800 shares. Based on an average daily volume of 741,700 shares, the short-interest ratio is currently 0.2 days. Approximately 5.5% of the company's stock are short sold. View Clearmind Medicine's Short Interest. How were Clearmind Medicine's earnings last quarter? Clearmind Medicine Inc. (NASDAQ:CMND) posted its quarterly earnings results on Monday, March, 18th. The company reported ($0.90) EPS for the quarter. What ETF holds Clearmind Medicine's stock? AdvisorShares Psychedelics ETF holds 128,641 shares of CMND stock, representing 2.24% of its portfolio. When did Clearmind Medicine's stock split? Clearmind Medicine shares reverse split on Tuesday, November 28th 2023. The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Clearmind Medicine IPO? Clearmind Medicine (CMND) raised $9 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 1,300,000 shares at a price of $6.00-$8.00 per share. Aegis Capital Corp. acted as the underwriter for the IPO. How do I buy shares of Clearmind Medicine? Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMND) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsIs this Nvidia's secret weapon?Manward PressCould Your Accounts Be Frozen?Allegiance GoldElon to Transform U.S. Economy? Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits“Crash Insurance” For Your RetirementUnstoppable ProsperityMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
